<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190523043678N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-06-11</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation  of Combination Nano micelle Curcumin with Triamcinolone Acetonide in Oral Lichen planus</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Effectiveness  of Combination Nano micelle Curcumin Gel %1with Triamcinolone Acetonide Mouthwash%0.1 in Oral Lichen planus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-10-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39854</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Four blocks are considered as two assignments for the intervention group and two allocations for the control group. Six possible modes of permutation of treatments are listed, and each one is written on a card. Each time a block is selected among them, and the order in the block is to be marked to allocate treatment for all 50 (12 blocks). Randomization is done by a design specialist. Hiding is done through the main investigator. On each of the 30 cards, we write a sequence of sequences and put them in sealed envelopes. The envelopes are placed in the box, respectively. For participants, the order of entry of one of the envelopes is allocated respectively, Blinding description: Curcumin gel and placebo gel are given in tubes of a shape and color to patients.
In this study, the investigator and patient do not know the type of drugs (double blind)
Examination of patients and evaluation of oral lesions before and after oral administration by one person.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral Lichen Planus.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: In this group, patients receiving 1% Nanocorcinem gel with triamcinolone mouthwash receive one-tenth of a percent for three weekly doses per week. (Half an hour after each meal, use a medication and use it for half an hour after eating and drinking). After using mouthwash for 5 minutes, the gel should be swallowed. This instruction is explained to all patients. Intervention 2: Control group: In this group, patients receiving placebo gel and triamcinolone mouthwash receive one-tenth of a percent for use at weekly intervals three times a day. (Half an hour after each meal, use a medication and use it for half an hour after eating and drinking). After using mouthwash for 5 minutes, the gel should be swallowed. This instruction is explained to all patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected data willbe shared after deidentification of participants

When:
6 mounth after publication data will become available

To whom:
The researchers in academic institutions

Conditions:
The researchers in academic institutions

Where to obtain:
The researchers in academic institutions can email responsible person and request information

How to obtain:
The researchers in academic institutions can email responsible person and request information

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahzad Gholami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Schoole of Dentistry:Daneshjoo  BLVD,Tabnak st,Chamran Highway,Tehran ,Iran</address>
        <city>Thehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1983963113</zip>
        <telephone>+98 21 2990 2311</telephone>
        <email>shahzad.kf@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahzad Gholami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Schoole of Dentistry:Daneshjoo  BLVD,Tabnak st,Chamran Highway,Tehran ,Iran</address>
        <city>Thehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>shahzad.kf@gmail.com</zip>
        <telephone>+98 21 2990 2311</telephone>
        <email>shahzad.kf@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with sympathetic lichen planus (erosive or atrophic) with burning or pain
Clinical diagnosis (Wicham lines) and in cases where it was difficult to achieve a definitive diagnosis of the lesion, a histopathologic evaluation was used
The patient has not been taking topical corticosteroid therapy over the past two weeks, he has not used systemic corticosteroids during the past month.
The patient has not used Analgesic and anestheticpain</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with lichenoid lesions caused by drugs or dental materials
pregnant or lactation
Patients who have other lesions similar to systemic leukoplakia and systemic lupus in conjunction with lichen planus
Historh of malignancy
Non-cooperative patients and patients who do not take medication</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lichen Planus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: In this group, patients receiving 1% Nanocorcinem gel with triamcinolone mouthwash receive one-tenth of a percent for three weekly doses per week. (Half an hour after each meal, use a medication and use it for half an hour after eating and drinking). After using mouthwash for 5 minutes, the gel should be swallowed. This instruction is explained to all patients.</i_keyword>
      <i_keyword>Control group: In this group, patients receiving placebo gel and triamcinolone mouthwash receive one-tenth of a percent for use at weekly intervals three times a day. (Half an hour after each meal, use a medication and use it for half an hour after eating and drinking). After using mouthwash for 5 minutes, the gel should be swallowed. This instruction is explained to all patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity and size of the lesion. Timepoint: Base Day (0), Day 14, Day 28. Method of measurement: with a scaled abslang.</prim_outcome>
      <prim_outcome>Reduction in severity of lessions. Timepoint: Base Day (0), Day 14, Day 28. Method of measurement: Efficacy Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-14</approval_date>
        <contact_name>Ethical committee of Shahid Beheshti University of Medical sciences.</contact_name>
        <contact_address>Schoole of Dentistry:Daneshjoo  BLVD,Tabnak st,Chamran Highway,Tehran ,Iran Thehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
